| Autor: |
Bougea A; 1st Department of Neurology, 'Aiginition' Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece., Angelopoulou E; 1st Department of Neurology, 'Aiginition' Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece., Vasilopoulos E; First Department of Psychiatry, 'Aiginition' Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece., Gourzis P; First Department of Psychiatry, 'Aiginition' Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.; Department of Psychiatry, University of Patras, 26504 Patras, Greece., Papageorgiou S; 1st Department of Neurology, 'Aiginition' Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece. |
| Abstrakt: |
Fluoxetine, a commonly prescribed medication for depression, has been studied in Alzheimer's disease (AD) patients for its effectiveness on cognitive symptoms. The aim of this systematic review is to investigate the therapeutic potential of fluoxetine in cognitive decline in AD, focusing on its anti-degenerative mechanisms of action and clinical implications. According to PRISMA, we searched MEDLINE, up to 1 April 2024, for animal and human studies examining the efficacy of fluoxetine with regard to the recovery of cognitive function in AD. Methodological quality was evaluated using the ARRIVE tool for animal AD studies and the Cochrane tool for clinical trials. In total, 22 studies were analyzed (19 animal AD studies and 3 clinical studies). Fluoxetine promoted neurogenesis and enhanced synaptic plasticity in preclinical models of AD, through a decrease in Aβ pathology and increase in BDNF, by activating diverse pathways (such as the DAF-16-mediated, TGF-beta1, ILK-AKT-GSK3beta, and CREB/p-CREB/BDNF). In addition, fluoxetine has anti-inflammatory properties/antioxidant effects via targeting antioxidant Nrf2/HO-1 and hindering TLR4/NLRP3 inflammasome. Only three clinical studies showed that fluoxetine ameliorated the cognitive performance of people with AD; however, several methodological issues limited the generalizability of these results. Overall, the high-quality preclinical evidence suggests that fluoxetine may have neuroprotective, antioxidant, and anti-inflammatory effects in AD animal models. While more high-quality clinical research is needed to fully understand the mechanisms underlying these effects, fluoxetine is a promising potential treatment for AD patients. If future clinical trials confirm its anti-degenerative and neuroprotective effects, fluoxetine could offer a new therapeutic approach for slowing down the progression of AD. |
